Strategy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Glenmark’s Lonhala Version Hits ‘Intriguing’ Indian Nebulizer Market
India Corporate Governance Practices – Will Pharma Walk The Gandhian Path?
Sun Claims It Played By Rulebook As Corporate Governance Allegations Smoulder
Big Changes At Bayer With Animal Health Exit And 12,000 Jobs Cut
The German company is making some dramatic changes to its structure and in terms of pharma R&D, the focus will be very much on external alliances.
Sun To Trim US Manufacturing, Over 90 Jobs At Stake
Sun Pharma is consolidating its production activities in the US transferring operations out of its Cranbury site to the one in New Brunswick. Close to 100 jobs are expected to be affected.
Pharma CEO Pay Up In India, Ratio Versus Employee Earnings Glaring
Eisai Seeks To Block Dr Reddy’s Over Belviq Plans In India
Eisai has moved court against Dr Reddy’s for alleged infringement of its patent on Belviq in India. The case is expected to put the spotlight back on prickly IPR issues, including working of patents.
Neuroscience Is The Next Oncology: Why Biogen Is Doubling Down
While other large biopharma companies are withdrawing from CNS research, Biogen is rare in not only staying in, but doubling down. Executives at the company’s 40th anniversary event in Switzerland explained why.
RedHill Unveils Plans For Pivotal Phase III Study For Crohn’s Therapy
RedHill Biopharma’s study results for its novel antibiotic approach to Crohn’s disease has left the company with some unanswered questions, despite hitting its endpoints in a recent Phase III study. Its COO, Gilead Raday, talks to Scrip about the next steps for the study.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.